Benchling Raises $100 Million in Funding and Continues European Expansion
Benchling raised $100 million to expand in Europe and further develop it's cloud-based R&D platform.
Benchling, developer of R&D Cloud software for the biotechnology industry, has raised $100 million in Series F funding, which it will use to continue its European expansion and further develop its cloud-based R&D platform, the company reported in a Nov. 18, 2021 press release.
The latest investment round was co-led by new investor Franklin Templeton and existing investor Altimeter Capital. Other new investors to join the existing ones in the financing round were Tiger Global and Lone Capital. As a result of the latest round of funding, Benchling is now valued at $6.1 billion.
“Biotechnology is rewriting life as we know it. Europe is at the forefront of cutting-edge R&D, and we are honored to work with nearly 100 companies there, after establishing a presence in Zurich last year. We are excited to double down our investment in this important market,” said Sajith Wickramasekara, CEO and co-founder of Benchling, in the press release. “Our customers, spanning nearly every major industry, are engineering more effective medicines, nutritious foods, and sustainable crops, materials, and fuels to address humanity’s most pressing issues. These challenges are global, so growth outside of the US is a strategic priority for us as we power modern, data-driven, and collaborative R&D.”
Source: Benchling
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
